A Phase I/II, Dose-escalation Study of Lipotecan Based Concurrent Chemoradiotherapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis
Phase of Trial: Phase I/II
Latest Information Update: 15 Nov 2018
Price : $35 *
At a glance
- Drugs TLC 388 (Primary)
- Indications Liver cancer; Thrombosis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Taiwan Liposome Company
- 04 Nov 2018 Status changed from recruiting to discontinued.
- 21 May 2017 Status changed from not yet recruiting to recruiting.
- 02 Feb 2017 New trial record